Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies.

Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G.

Clin Cancer Res. 2009 Feb 15;15(4):1460-5. doi: 10.1158/1078-0432.CCR-08-1599.

2.

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G.

Invest New Drugs. 2011 Dec;29(6):1465-74. doi: 10.1007/s10637-010-9455-x. Epub 2010 May 25.

3.

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.

Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD.

Cancer Biol Ther. 2006 Jan;5(1):22-7. Epub 2006 Jan 22.

PMID:
16357512
4.

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C.

Gynecol Oncol. 2009 Oct;115(1):90-6. doi: 10.1016/j.ygyno.2009.05.042. Epub 2009 Jul 4.

PMID:
19577796
5.

Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.

James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD.

Invest New Drugs. 2007 Feb;25(1):41-8. Epub 2006 Sep 13.

PMID:
16969706
6.

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.

Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR.

Invest New Drugs. 2011 Apr;29(2):340-6. doi: 10.1007/s10637-009-9383-9. Epub 2010 Jan 19.

8.

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS.

Cancer Chemother Pharmacol. 2011 Aug;68(2):293-300. doi: 10.1007/s00280-010-1478-7. Epub 2010 Oct 20.

9.

Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.

Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC.

Phytomedicine. 2010 Mar;17(3-4):161-9. doi: 10.1016/j.phymed.2009.12.016. Epub 2010 Jan 22.

PMID:
20092990
10.

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.

Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.

Clin Cancer Res. 2008 Feb 15;14(4):1111-5. doi: 10.1158/1078-0432.CCR-07-4097.

11.

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.

Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF, Anderson KC, Gertz MA.

Clin Cancer Res. 2007 Oct 15;13(20):6162-7.

12.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.

Clin Cancer Res. 2002 Mar;8(3):718-28.

13.

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML.

Clin Cancer Res. 2006 May 1;12(9):2834-40.

14.

Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.

Robinson MR, Baffi J, Yuan P, Sung C, Byrnes G, Cox TA, Csaky KG.

Exp Eye Res. 2002 Feb;74(2):309-17.

PMID:
11950241
15.

A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.

Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, McMeekin DS, Benhadji KA, Patel BK, Frenzel MJ, Kursar JD, Zamek-Gliszczynski MJ, Yuen ES, Chan EM, Bendell JC.

Eur J Cancer. 2016 Mar;56:1-9. doi: 10.1016/j.ejca.2015.11.021. Epub 2016 Jan 19.

16.

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, J├╝rgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C.

J Clin Oncol. 2007 Jul 20;25(21):3045-54.

PMID:
17634482
17.

A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM.

Clin Cancer Res. 2012 Nov 1;18(21):6011-22. doi: 10.1158/1078-0432.CCR-11-3284. Epub 2012 Sep 7.

18.

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.

Wong AL, Soo RA, Tan DS, Lee SC, Lim JS, Marban PC, Kong LR, Lee YJ, Wang LZ, Thuya WL, Soong R, Yee MQ, Chin TM, Cordero MT, Asuncion BR, Pang B, Pervaiz S, Hirpara JL, Sinha A, Xu WW, Yuasa M, Tsunoda T, Motoyama M, Yamauchi T, Goh BC.

Ann Oncol. 2015 May;26(5):998-1005. doi: 10.1093/annonc/mdv026. Epub 2015 Jan 21.

PMID:
25609248
19.

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH.

Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10.

Supplemental Content

Support Center